Introduction
============

Lung adenocarcinoma, predominantly developed from pre-malignancy lung adenomas, leads estimate 910,000 incidence and 800,000 mortality annually worldwide ([@B12]; [@B18]). Pathological study revealed that cellular senescence, an intrinsic and irreversible suicide program, is accelerated in lung adenomas while strikingly diminished in LAC, suggesting senescence is a critical physiological barrier against tumor progression ([@B10]). Furthermore, during chemotherapy and radiation, a robust of senescence stimulation is also found to synergistically determine cancer prognosis and systemic toxicity. For instance, loss of p14^ARF^-dependent senescence correlated with poor outcome of non-small cell lung cancer ([@B21]). Meanwhile, parallel to apoptosis activation, chemotherapy-induced senescence predominately triggered regenerative response against systemic toxicities including bone marrow suppression and gastrointestinal toxicity ([@B36]). Due to intrinsic and primary physiological response against tumorigenesis, senescence-targeting approach were estimated to cause fewer feedback signaling alterations ([@B17]) compared to other targeted chemotherapeutic agents such as gefitinib, afatinib, and cetuximab ([@B19]). Moreover, "synthetic senescent interaction" could be also achieved by combining *Kras* activation with *Cdk4* loss, *Myc* stimulation with *Cdk2* depletion ([@B6]; [@B33]). Therefore, pro-senescence therapy is regarded as a novel and promising strategy for cancer eradication.

Cellular senescence, a stable proliferative arrest in normal cells, is triggered by a combination of four major mechanisms: telomere shortening-dependent replicative senescence (RS), oncogene-induced senescence (OIS), tumor suppressor gene (TSG) inactivation, as well as stress-induced senescence ([@B30]). RS, also known as replicative senescence often depends on telomere dysfunction induced by replication-associated telomere shortening ([@B31]). OIS depends on activation or overexpression of oncogenes such as RAS and BRAF^V\ 600E^ activation ([@B43]). TSG depends on tumor suppressor inactivation or loss, such as PICS ([@B39]). During each type of senescence, various phenotypes were consequently altered such as senescence-associated β-galactosidase activity (SA-β-gal), formation of SAHF, and sustained DDR ([@B31]). Subsequently, p53, p21^waf^, and p16 are activated while cyclin-dependent kinases including CDK4 and CDK6 are contrarily suppressed in senescent cells ([@B31]). Meanwhile, some of epigenetic modifiers were also involved such as H3K9 histone methyltransferase and polycomb complexes including H3K36 demethylase and H3K27 demethylase ([@B13]). Compared to other senescence mechanisms, stress-induced senescence plays a comprehensive and predominant role in tumor initiation by widely altering genomic and epigenetic landscapes. ROS, one of the earliest responses toward oxidative stress, exerts various functions even with apparently opposite outcomes. Concretely speaking, intercellular ROS accumulation effectively stimulated cell hyperproliferation via activating mitogenic pathway, whereas at the meantime, ROS contrarily suppressed DNA replication though causing DDR-p53/p21^waf^ signaling ([@B30]). Thus, given the controversial role of ROS-induced senescence in tumorigenesis, the mechanisms underlying still need extensively investigation. At the meantime, considering the vital role of ROS in tumor initiation, developing an effective ROS-dependent pro-senescence agent is also urgent need for clinical chemoprevention.

Until now, various pro-senescence agents were developed and some of them have been entered into clinical trials such as GRN163L, nutlin, and MIRA-1 ([@B1]; [@B5]). However, systemic toxicity and drug resistance greatly limited their clinical applications. SHK, a pure compound isolated from the herbal medicine *Lithospermum erythrorhizon*, exhibited anti-inflammatory, antitumor, and antiviral effectiveness with tolerable toxicity ([@B7]; [@B26]). Previous studies indicated that SHK could significantly inhibit lung carcinogenesis by stimulating apoptosis and arresting cell cycle ([@B22]). Meanwhile, SHK also effectively suppressed tumor metastasis via suppressing ERK1/2 signaling ([@B41]). Also, SHK shown to induce apoptosis, senescence and necrosis through up regulating p53 in A549 cells ([@B45]). Furthermore, in gefitinib-resistance lung cancer cells, SHK was also reported to sensitize chemotherapeutic efficacy by inhibiting TrxR while activating EGFR proteasomal degradation ([@B23]). However, whether SHK could trigger ROS generation in lung cancer cells is unknown, and whether SHK-induced senescence depends on ROS generation also remains unclear.

In our present study, the pro-senescence effects and mechanisms of SHK were determined in A549 and H1299 cells *in vitro* and xenograft models *in vivo*. We found that SHK significantly inhibited tumor proliferation via stimulating cellular senescence. Further mechanistic study revealed that SHK-induced senescence was dependent on ROS generation with increasing DNA damage (p-H2A.X), p53 (total and phosphorylation), and p21^waf^. Our study suggested that SHK, a ROS-dependent senescence inducer, could serve as a promising agent for further lung cancer treatment, and even chemoprevention.

Materials and Methods {#s1}
=====================

Reagents and Cell Culture
-------------------------

SHK (purity \> 98%) was purchased from Chengdu Must Bio-technology Co., Ltd. (Chengdu, China). MTT and NAC were purchased from Sigma-Aldrich (St. Louis, MO, United States). PI staining was purchased from Biosciences (BD Biosciences, Franklin Lakes, NJ, United States). β-actin, MEK-1, p53 and p21^waf^ primary antibodies and HRP-conjugated secondary antibody were purchased from Santa Cruz Biotechnologies Inc. (Santa Cruz, CA, United States). Bcl-2, Bax, Rb, Cleaved Caspase-3, Ras, H3K36me2, p-p53, p-H2A.X, Histone H3 and Cyclin D1 antibodies were purchased from Cell Signaling Technology Inc. (Beverly, MA, United States). Kdm2b antibody was purchased from Millipore (Burlington, MA, United States). p16 antibody was purchased from Abcam (Cambridge, United Kingdom). Specific small interfering RNA (siRNA) of p21 and riboFECTTM CP Transfection Kit (166T) were purchased from Ribobio, Co., Ltd (Guangdong, China). Two human LAC cells (A549 and H1299) were purchased from ATCC (Manassas, VA, United States). A549 and H1299 cells were maintained in RPMI-1640 medium with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin solution, and cultured in a humidified atmosphere at 37°C with 5% CO~2~.

MTT Assay
---------

Cells were seeded into 96-well plates at 2 × 10^3^ cells/well. After cultured overnight, cells were treated with SHK (0--6 μM) for 24, 48, and 72 h. Cells were incubated with the MTT solution (0.5 mg/mL) at 37°C for 4 h. The supernatants were replaced by dimethyl sulfoxide (150 μL/well). Then the absorbance was measured using microplate reader Victor X3 (PerkinElmer, Waltham, MA, United States) at 490 nm. The half inhibitory concentration (IC~50~) was obtained using the non-linear regression program of GraphPad Prism 5.

5-Ethynyl-2′-deoxyuridine (EdU) Assay
-------------------------------------

EdU, a nucleoside analog of thymidine which is in corporated into DNA during active DNA synthesis, is often used to measure cell proliferation. Cells were seeded into 96-well plates at 2 × 10^3^ cells/well, and treated with SHK (1 and 2 μM for A549, 0.3 and 0.6 μM for H1299, respectively) for 72 h. Then cells were incubated with EdU labeling medium (50 μM) for 2 h at 37°C with 5% CO~2~, fixed with 4% paraformaldehyde (pH = 7.4) for 30 min, and incubated with glycine for 5 min. After rinsed with PBS, cells were incubated with anti-EdU working solution at room temperature for 30 min, following with Hoechst 33342 dye (1×) at room temperature for 30 min. The images were captured using Leica3000B (Leica, GER). The percentages of EdU-positive cells were calculated from five random fields in two wells.

Cell Cycle Analysis
-------------------

Cells were seeded into 6-well plates at 6 × 10^4^ cells/well and treated with SHK (1 and 2 μM for A549, 0.3 and 0.6 μM for H1299, respectively) for 72 h. Following, cells were harvested, washed twice with PBS, and fixed with 70% cold ethanol at 4°C overnight, then stained with PI (50 μg/mL) at 37°C for 0.5 h protecting from light. Cell cycle was detected by flow cytometry (BD Biosciences, San Jose, CA, United States). The results were analyzed by FlowJo 7.6 software.

Detection of Senescence-Associated Heterochromatin Foci (SAHF)
--------------------------------------------------------------

SAHF are specialized domains of facultative heterochromatinin senescent cells. 4′,6-diamidino-2-phenylindole (DAPI) staining was used to observe SAHF. Cells were seeded into 15 mm confocal dish at 3 × 10^4^ cells/well, cultured overnight, then treated with SHK (2 μM for A549 and 0.6 μM for H1299, respectively) for 72 h. After harvested, cells were fixed in 4% cold paraformaldehyde, incubated with DAPI for 10 min. The images were captured using Leica TCS SP8 confocal microscope (Leica, GER). All images were acquired using an identical parameter time for all samples.

Senescence-Associated β-Galactosidase (SA-β-Gal) Assay
------------------------------------------------------

Cells were seeded into 6-well plates at 6 × 10^4^ cells/well and treated with SHK (1 and 2 μM for A549, 0.3 and 0.6 μM for H1299, respectively) for 72 h. Then cells were stained with SA-β-Gal in accordance to the manufacturer's procedure of Senescent Cell Histochemical Staining Kit (CST). Meanwhile, tumor tissues were frozen and sliced up (4 μm). Then the frozen sections were stained immediately with SA-β-Gal in accordance to the manufacturer's procedure of Senescent Cell Histochemical Staining Kit (CST).

ROS Detection
-------------

Reactive oxygen species formation in cells was detected using Cellular Reactive Oxygen Species Detection Assay Kit (Abcam, United Kingdom), according to the manufacturer's instruction. Briefly, cells were seeded into 6-well plates at 6 × 10^4^ cells/well and treated with SHK (1 and 2 μM for A549, 0.3 and 0.6 μM for H1299, respectively) for 72 h. Then the cells were collected and washed twice with PBS and suspended in PBS-H~2~DCFDA (10 μM) at 37°C for 30 min. After that, the fluorescence was monitored by flow cytometry.

siRNA Interference
------------------

The siRNA was used to interfere the gene and protein expressions of p21^waf^. The sequence of siRNA was: GAATGAGAGGTTCCTAAGA. Cells were seeded into 6-well plates at 3 × 10^5^ cells/well, and transfected with 50 nM siRNA or negative control using riboFECTTM CP Transfection Kit (166T) in serum free Opti-MEM media according to the manufacturer's protocal. After 12 h transection, the cells were digested and seeded into new 6-well plates at a density of 1 × 10^5^ cells/well, and cultured overnight, then the cells were continuously cultured with or without SHK (2 μM for A549 and 0.6 μM for H1299, respectively) for 72 h. Finally, cells were harvested for following assay.

Western Blot
------------

After cells were harvested, total proteins were extracted using RIPA lysis buffer and phenylmethanesulfonyl fluoride (PMSF), and quantified using Coomassie Brilliant Blue Kit (Bio-Rad, Hercules, CA, United States). Protein samples were separated by SDS-PAGE, transferred onto PVDF membranes, and blocked with 5% BSA for 1 h, and then incubated with the primary antibodies at 4°C overnight, subsequently, with secondary antibodies at room temperature for 1 h. ECL chemiluminescence reagent was applied to detect for fluorescent signals using FluorChem E (Santa Clara, CA, United States). Protein bands were quantified using Quantity One software (Bio-Rad, Hercules, CA, United States).

Apoptosis Detection
-------------------

Cells were seeded into 6-well plates at 6 × 10^4^ cells/well and treated with SHK (1 and 2 μM for A549, 0.3 and 0.6 μM for H1299, respectively) for 72 h. After harvested, cells were processed using the FITC annexin V/PI Apoptosis Detection Kit (BD Biosciences, United States), according to the manufacturer's protocol. After that, cell apoptosis was analyzed by the flow cytometry.

Immunofluorescence
------------------

Cells were seeded into 15 mm confocal dish 3 × 10^4^ cells/well, cultured overnight, then treated with SHK (1 and 2 μM for A549, 0.3 and 0.6 μM for H1299, respectively) for 72 h. After harvested, cells were fixed in 4% cold paraformaldehyde, incubated with the primary antibodies at 4°C overnight, and with Alexa Fluor^®^ conjugated secondary antibodies (1:500, v/v) at room temperature for 1 h protecting from light. The images were captured using Leica TCS SP8 confocal microscope (Leica, GER). All images were acquired using an identical parameter time for all samples.

NSCLC Xenograft Mice Models
---------------------------

Female Balb/c-nude mice (4--6 weeks, 16--20 g) were purchased from Laboratory Animal Center of Sun Yat-sen University \[Guangzhou, China; License number: SCXK (Guangdong) 2016-0029\], and kept in the animal facility in the SPF animal laboratory \[License number: SYXK (GZ) 2014-0144\] at International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine (Guangzhou, China). The animal experiments were approved by the Guangzhou University of Chinese Medicine Animal Care and Use Committee (Guangzhou, China), and conducted according with the ethical standards and national guidelines. For A549 xenograft model, mice were subjected to subcutaneously injection with A549 cells (2.5 × 10^6^ cells/mouse) in each right flank. Tumor volume (TV), defined based on two dimensions (L, long diameter; W, wide diameter), was measured by calipers, and calculated as formula: TV (mm^3^) = (L × W^2^)/2. When the tumors reached a mean volume of 50 mm^3^, eligible mice were randomized into four groups (*n* = 7) as following: gavage control (sterilized coin oil), afatinib (5 mg/kg), SHK (5, 10 mg/kg). For H1299 xenograft model, mice were subjected to subcutaneously injection with H1299 cells (3 × 10^6^ cells/mouse) in each right flank. When the tumors reached a mean volume of 50 mm^3^, the mice were randomized into two groups (*n* = 7) as following: gavage control (sterilized coin oil), SHK (10 mg/kg). Animals received oral administration with drugs five times a week for 4 weeks. Body weights were recorded every 3 days. At the end of the experiments, mice were sacrificed, and the tumors and organs were removed and weighed for following assays.

Immunohistochemistry
--------------------

Tumor tissues were fixed in 4% paraformaldehyde, embedded in paraffin, and then sliced up (4 μm). Then slices were dewaxed, hydrated, and then incubated with natrium citric (0.01 M) for antigen retrieval. Following, the slices were rinsed with PBS, and incubated with diluted anti-p-H2A.X, anti-p53 and anti-p21 overnight at 4°C. Following steps were performed using the immunostaining kit (BOSTER Biological Technology) based on the manufacturer's instructions.

Statistical Analysis
--------------------

All data were expressed as the mean ± standard deviation (SD). Significant differences were analyzed by one-way analysis of variance (ANOVA) followed by the LSD *post hoc* test using SPSS 19.0 software. Statistical differences were considered significant at *p* \< 0.05.

Results
=======

SHK Suppressed Lung Cancer Cell Proliferation via Arresting Cell Cycle at G0/G1 Phase
-------------------------------------------------------------------------------------

To determine the cytotoxicity of SHK (**Figure [1A](#F1){ref-type="fig"}**), cell viabilities were evaluated at 24, 48, and 72 h, respectively by MTT assay. SHK dose- and time-dependently suppressed viable cell percentages in A549 and H1299 cells, and the respective IC~50~ were 2.28 ± 0.19 and 0.64 ± 0.07 μM at 72 h (**Figure [1B](#F1){ref-type="fig"}**). Therefore, considering diverse SHK sensitivity observed in these two cells, 1 and 2 μM of SHK were selected for further treatments in A549 cells, while 0.3 and 0.6 μM were applied to H1299 cells according to the equivalent viability in A549 cells.

![Effects of SHK on cell proliferation and cell cycle arrest. **(A)** Chemical structure of SHK (MW = 288.3). **(B)** Cell viabilities of A549 and H1299 cells were measured by MTT assay after treatment with SHK (0--6 μM) for 24, 48, and 72 h. **(C)** EdU incorporation was evaluated after SHK treatments for 72 h, and mean EdU fluorescences in SHK treatments were relative to that in control treatment, which was arbitrarily set as 100. **(D)** Percentages of cell cycle arrest were analyzed by flow cytometry after SHK treatments. **(E)** Expression of Cyclin D1 in A549 and H1299 cells after SHK treatments. Data represent mean ± SD (*n* = 3). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 *vs*. Ctrl (control).](fphar-09-00519-g001){#F1}

Furthermore, EdU assay and flow cytometry were performed to analyze the effect of SHK on lung cancer cell proliferation. Given the cytotoxicity of SHK found previously (**Figure [1B](#F1){ref-type="fig"}**), the average percentages of EdU fluorescence, rather than the absolute EdU-labeling cell numbers, in each treatment were analyzed accordingly ([@B44]). In contrast to the abundant EdU-positive cells observed in control (Ctrl, 0.1% DMSO, same as follows), SHK at 1 and 2 μM significantly suppressed A549 cell proliferation ratio by 44.00% ± 2.22% and 84.42% ± 4.57% (**Figure [1C](#F1){ref-type="fig"}**, *P* \< 0.001). Simultaneously, SHK at 2 μM notably increased the percentage of A549 cells at G0/G1 phase from 45.79% ± 2.27% in control treatment to 54.12% ± 0.10% (**Figure [1D](#F1){ref-type="fig"}**, *P* \< 0.001). Similarly, remarkable inhibition of EdU fluorescence (range 36.51--67.44%) were also found in H1299 cells after treatment with 0.3 and 0.6 μM of SHK (**Figure [1C](#F1){ref-type="fig"}**, *P* \< 0.001). And 0.3 and 0.6 μM of SHK also markedly arrested H1299 cells at G0/G1 phase by 13.78% ± 0.58% and 19.81% ± 0.47% (**Figure [1D](#F1){ref-type="fig"}**, *P* \< 0.001). Moreover, given the significant G0/G1 arrest in A549 and H1299 cells, cyclin D1, a key protein required for progression through the G1 phase of the cell cycle ([@B37]) was further determined. Compared to control treatment, SHK at 2 and 0.6 μM significantly decreased the expression of cyclin D1 by 35.21% ± 8.17% and 24.25% ± 5.73% in A549 and H1299 cells, respectively (**Figure [1E](#F1){ref-type="fig"}**, *P* \< 0.01).

SHK Notably Promoted Cell Senescence in A549 and H1299 Cells
------------------------------------------------------------

Considering two key phenotypes of senescence, G0/G1 arrest ([@B25]) (**Figure [1D](#F1){ref-type="fig"}**) and cell relative enlargement ([@B28]) (**Figure [1C](#F1){ref-type="fig"}**), were unexpectedly observed after our SHK treatments, we hypothesized that SHK might influence senescence to suppress cell proliferative capacity in A549 and H1299 cells. Thus, the effects of SHK in senescence were further determined by SAHF detection ([@B20]) and SA-β-Gal staining ([@B15]).

SAHF, specialized domains of facultative heterochromatin, are predominately contributed to cellular senescence through repressing proliferative-promoting proteins such as cyclin A and D ([@B4]; [@B24]). To elucidate mechanism underlying the SHK-induced cell cycle arrest observed in **Figure [1D](#F1){ref-type="fig"}**, SAHF was detected by confocal microscope. Since most of cellular morphological observation was not closely dependent on dosage, only relative high doses of SHK (2 and 0.6 μM respectively in A549 and H1299 cells) were used. After treatment with SHK, the chromosomes in control were markedly condensed into numerous SAHF focus. In addition, compared to H1299 cells, SAHF focus was abundantly condensed in A549 cells, suggesting A549 was more sensitive for SHK-induced senescence (**Figure [2A](#F2){ref-type="fig"}**). Furthermore, both in A549 and H1299 cells, SHK remarkably altered cellular morphology from spindle and round to flat and enlarged, and the presence of vacuoles were also observed, especially in A549 cells (**Figures [2B,C](#F2){ref-type="fig"}**). Meanwhile, the proportions of senescent cells, positively labeled by β-Gal ([@B8]), were also gradually increased by SHK (**Figure [2C](#F2){ref-type="fig"}**), either in A549 cells (induction ranging from 3.77- to 6.89-fold) (*P* \< 0.001) or in H1299 cells (induction ranging from 2.10- to 4.83-fold) (*P* \< 0.01 or *P* \< 0.001).

![SHK induced senescence in A549 and H1299 cells. **(A)** Representative confocal imaging (scale bar: 7.5 μm) of SAHF in A549 and H1299 cells after SHK treatment using DAPI (blue) staining. **(B)** Morphologic changes of A549 and H1299 cells were observed after SHK treatment. **(C)** The proportions of senescence A549 and H1299 cells were determined using SA-β-Gal staining after SHK treatments. ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 *vs*. Ctrl (control).](fphar-09-00519-g002){#F2}

SHK Induced Cellular Senescence Through Stimulating ROS Generation and Subsequently Triggering DNA Damage-p53/p21^waf^ Axis
---------------------------------------------------------------------------------------------------------------------------

Cellular senescence is predominantly triggered via either oncogenes activation (RAS and BRAF^V\ 600E^) or depletion of tumor suppressor genes \[TSG: PTEN, RB, and CDKN2A (encoding p16 protein)\] ([@B29]). Herein, to further determine the mechanism underlying SHK-induced cell senescence, Ras, MEK-1, Rb, and p16 expressions were evaluated only in A549 cells due to the abnormal basal expressions of oncogenes and TSG in p53-deleted H1299 cells. Rather than activation, Ras and MEK-1 expressions were unexpectedly decreased by SHK (**Figure [3A](#F3){ref-type="fig"}**, *P* \< 0.05), meanwhile, no significant differences were observed on Rb and p16 expressions (**Figure [3A](#F3){ref-type="fig"}**), suggesting that oncogene and TSG maybe not the main driver factors in SHK-induced senescence.

![The underlying mechanism of SHK-induced senescence in A549 and H1299 cells. **(A)** Expressions of Ras, MEK-1, p16 and Rb in A549 cells after SHK treatments. **(B)** Levels of ROS generation in A549 and H1299 cells were detected by flow cytometry after SHK treatments. **(C)** Expressions of Kdm2b and H3K36me2 were measured by Western blot after SHK treatments. **(D)** Expressions of p53 and p21^waf^ in total protein, and p-p53 in nuclei were determined by Western blot after SHK treatments. **(E)** Expressions of p21^waf^ in H1299 cells were measured by Western blot after SHK treatments. **(F)** Expressions of p21^waf^ in A549 and H1299 cells transfected with siRNA after SHK treatments. **(G)** Representative SA-β-Gal staining imaging (scale bar: 50 μm) of A549 and H1299 cells transfected with siRNA after SHK treatments. **(H)** Expression of p-H2A.X was inspected by Western blot after SHK treatments. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 *vs*. Ctrl (control), ^\#\#\#^*P* \< 0.001 *vs*. SHK.](fphar-09-00519-g003){#F3}

On the contrary, ROS production was notably increased by SHK (ranging from 0.32- to 3.36-fold in A549 cells and 3.15- to 15.31-fold in H1299 cells) (**Figure [3B](#F3){ref-type="fig"}**, *P* \< 0.01). Meanwhile, Kdm2b/JHDM1b, an H3K36me2-specific demethylase involved in cellular senescence, was reported to effectively suppress ROS generation ([@B32]). After SHK treatment, we found that the expression of Kdm2b was significantly decreased in A549 and H1299 cells (**Figure [3C](#F3){ref-type="fig"}**, *P* \< 0.01). In contrast, the protein level of H3K36me2 was dramatically increased with remarkable inductions (**Figure [3C](#F3){ref-type="fig"}**, *P* \< 0.01).

Previous study revealed that ROS contributed to cell senescence through the activation of the p53/p21^waf^ pathway ([@B2]). Thus, to further determine the mechanism of SHK-induced senescence and ROS generation, p53 and its downstream target p21^waf^ were evaluated. As shown in **Figure [3D](#F3){ref-type="fig"}**, in A549 cells, SHK effectively stimulated p53 transcription, and subsequently induced p21^waf^ expression (*P* \< 0.001). Meanwhile, the phosphorylated p53 in nucleus was significantly increased by SHK (**Figure [3D](#F3){ref-type="fig"}**, *P* \< 0.01). Whereas, in p53-deleted H1299 cells, the presence of p21^waf^ could alternatively lead to growth arrest and differentiation in a p53-independent manner ([@B42]). Accordingly, we also observed that SHK at 0.3 and 0.6 μM could markedly induced p21^waf^ protein level by 1.76- and 2.00-fold, respectively (**Figure [3E](#F3){ref-type="fig"}**, *P* \< 0.01). To further confirm the role of p21^waf^ in SHK-induced senescence, p21^waf^ was knock-down in A549 and H1299 cells. The mRNA and protein expressions of p21^waf^ in A549 and H1299 cells were obviously down-regulated by siRNA (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). After siRNA interference, p21^waf^ expression was remarkably reduced by 71.90% and 65.52%, respectively, compared to that in SHK treated cells (**Figure [3F](#F3){ref-type="fig"}**). Moreover, siRNA interference also significantly reversed SHK-induced senescence in this two cell lines (**Figure [3G](#F3){ref-type="fig"}**).

Previous study suggested that after senescence induction, the activation of p53/p21^waf^ pathway was triggered by sever DDR ([@B16]). Compared to control treatment, SHK at 1 and 2 μM enhanced the expressions of p-H2A.X, sensor for DNA damage, by 1.97- and 3.47-fold, respectively in A549 cells; while that were also increased by 0.3 and 0.6 μM of SHK with respective induction of 4.68- and 8.03-fold in H1299 cells (**Figure [3H](#F3){ref-type="fig"}**, *P* \< 0.01).

SHK-Induced Senescence Was Specifically Dependent on ROS Generation
-------------------------------------------------------------------

To evaluate whether SHK-induced senescence is dependent on ROS, NAC, a classic ROS scavenger was used in our further study. Compared to low intercellular ROS level in control treatment, no significant alteration was observed after treatment with NAC (2 mM). While, NAC pretreatment notably attenuated SHK-induced intracellular ROS generation by 89.55% ± 0.99% and 75.52% ± 1.35% in A549 and H1299 cells, respectively (**Figure [4A](#F4){ref-type="fig"}**, *P* \< 0.001).

![SHK-induced senescence is specifically dependent on ROS generation. **(A)** ROS generations in A549 and H1299 cells were detected by flow cytometry after 1 h of NAC (2 mM) pretreatment and 72 h of SHK treatment. **(B)** Cell viabilities of A549 and H1299 were determined in the presence of 2 mM NAC pretreatment for 1 h. **(C)** The proportions of senescence A549 and H1299 cells were determined using SA-β-Gal staining after NAC pretreatment and SHK treatment. **(D)** Expressions of p53 and p21^waf^ in A549 cells, and expression of p21^waf^ in H1299 cells were detected by Western blot after NAC pretreatment and SHK treatment. **(E)** Representative confocal imaging (scale bar: 25 μm) of double-stained cells after NAC pretreatment and SHK treatment using p-H2A.X (red) and DAPI (blue) staining. ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 *vs*. Ctrl (control), ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001 *vs*. SHK.](fphar-09-00519-g004){#F4}

In contrast to gradually suppressed cell viability in SHK treatments, pretreated with NAC successfully reversed the cytotoxicity of SHK in A549 and H1299 cells in dose-dependent manner (**Figure [4B](#F4){ref-type="fig"}**). At the same time, SA-β-Gal staining results also showed that NAC pretreatment markedly reduced the percentages of SHK-induced senescent cells by 82.64% ± 5.68% and 73.47% ± 6.63% in A549 and H1299 cells, respectively (**Figure [4C](#F4){ref-type="fig"}**, *P* \< 0.001). And the morphologies of SHK-induced enlarged and flat senescent cells were also effectively reversed by NAC to spindle and round (**Figure [4C](#F4){ref-type="fig"}**). Moreover, SHK-induced p53 and p21^waf^ activation was also completely reversed by pretreated with NAC in A549 cells, as well as that of p21^waf^ activation in H1299 cells (**Figure [4D](#F4){ref-type="fig"}**). Additionally, immunofluorescence results also revealed that both in A549 and H1299 cells, SHK-induced p-H2A.X over-expressions were dramatically diminished by NAC pretreatment (**Figure [4E](#F4){ref-type="fig"}**).

SHK-Induced Apoptosis Was Dependent on ROS Generation
-----------------------------------------------------

Emerging evidence demonstrated that cytotoxic chemotherapeutic agents simultaneously stimulated a robust cellular senescence to achieve "synthetic senescent interaction," but the extent of senescence and apoptosis is unknown ([@B9]). Meanwhile, previous study also revealed that apoptosis is the ultimate biological consequence for senescent cells *in vivo* ([@B3]). Thus, apoptosis ratio was analyzed subsequently in A549 cells, which were more sensitive toward SHK-induced senescence (**Figures [2A](#F2){ref-type="fig"}--[C](#F2){ref-type="fig"}**). Compared to control treatment, SHK significantly increased early and late phases of apoptosis, especially SHK at 2 μM induced that by 4.55- and 3.96-fold, respectively (**Figure [5A](#F5){ref-type="fig"}**, *P* \< 0.001). However, compared to the significantly stimulated senescence in A549 cell (range 38.70%--70.69%, **Figure [2C](#F2){ref-type="fig"}**), the percentage of total apoptosis is extremely low (range 3.13%--7.65%, **Figure [5A](#F5){ref-type="fig"}**). These implied that rather than apoptosis, the predominant effect of SHK on LAC cells was stimulating senescence.

![SHK-induced apoptosis depending on ROS generation. **(A)** The proportions of apoptosis cells of A549 were determined by flow cytometry using FITC annexin V/PI double staining assay after SHK treatments. **(B)** Expressions of Bcl-2, Bax and Cleaved Caspase-3 were measured by Western blot after SHK treatments. **(C)** The proportions of apoptosis cells of A549 were determined by flow cytometry after NAC pretreatment and SHK treatment using FITC annexin V/PI double staining assay. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 *vs*. Ctrl (control), ^\#\#\#^*P* \< 0.001 *vs*. SHK.](fphar-09-00519-g005){#F5}

Moreover, western blot results also showed that compared with control treatment, SHK markedly decreased the expression of anti-apoptosis protein Bcl-2, while that of pro-apoptotic Bax and Cleaved Caspase-3 were significantly increased. Meanwhile, SHK simultaneously decreased Bcl-2/Bax ratio, a parameter determined the susceptibility of cellular apoptosis, by 43.35% ± 2.60% and 67.74% ± 2.42%, respectively (**Figure [5B](#F5){ref-type="fig"}**, *P* \< 0.001). Moreover, NAC pretreatment significantly diminished SHK-induced apoptosis from 8.87% ± 1.17% to 2.70% ± 0.17% in A549 cells (**Figure [5C](#F5){ref-type="fig"}**, *P* \< 0.001).

SHK Suppressed Lung Cancer Growth in NSCLC Xenograft Mice Models
----------------------------------------------------------------

To further determine the anti-tumor effect of SHK-induced senescence, A549 xenograft model was established. Afatinib, a tyrosine kinase inhibitor normally used as a first-line chemotherapeutic agent for LAC, was reported to induce irreversible senescence to substantially suppress tumor progression ([@B27]). Given SHK is supposed to be a good senescence-targeting agent in our study, afatinib was used as positive control. After orally gavage SHK and afatinib for 4 weeks, no significant alterations on average body weight were observed among treatments (**Figure [6A](#F6){ref-type="fig"}**). Meanwhile, compared to control treatment (Corn oil), SHK, either at 5 mg/kg or at 10 mg/kg, did not remarkably alter the tissue indexes including heart, liver, spleen, lung, and kidney (Supplementary Figure [S2A](#SM1){ref-type="supplementary-material"}), suggesting no systemic toxicity was observed after SHK treatments.

![Inhibitory effects of SHK in A549 xenograft mice model. **(A)** Average body weight curves of Balb/c-nude mice (*n* = 7). **(B)** Tumor volume ((L × W^2^)/2, L, long diameter; W, wide diameter) were analyzed. **(C)** Tumors were photographed and tumor weights were analyzed. **(D)** Images of senescence cells in tumor consecutive frozen sections using SA-β-Gal staining assay (scale bar: 50 μm). **(E)** Images of tumor p-H2A.X, p53 and p21^waf^ protein expressions were presented by immunohistochemistry (scale bar: 50 μm). ^∗^*P* \< 0.05, ^∗∗∗^*P* \< 0.001 *vs*. Ctrl (control).](fphar-09-00519-g006){#F6}

Notably, SHK dose-dependently suppressed tumor growth (**Figure [6B](#F6){ref-type="fig"}**), tumor size and tumor weight (**Figure [6C](#F6){ref-type="fig"}**). Meanwhile, compared to control, SHK at 5 mg/kg and 10 mg/kg also significantly decreased the tumor weights by 28.57% and 55.84%, respectively (**Figure [6C](#F6){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**, *P* \< 0.05).

###### 

The inhibitory effects of SHK on A549 xenograft mice.

  Groups     Dose (mg/kg)   Routes     Numbers   Body weight (g)   Tumor weight (g)   Inhibitory rate (%)
  ---------- -------------- ---------- --------- ----------------- ------------------ ---------------------
  Control    Corn oil       p.o.(qd)   7/7       21.2 ± 1.46       1.54 ± 0.44        
  SHK        5              p.o.(qd)   7/7       20.3 ± 0.8        1.10 ± 0.38        28.57
  SHK        10             p.o.(qd)   7/7       19.9 ± 0.86       0.68 ± 0.14        55.84
  Afatinib   5              p.o.(qd)   7/7       20.3 + 1.22       0.37 ± 0.13        75.97

To evaluate whether the anti-tumor effect of SHK ascribe to senescence induction, cellular senescence, and the expressions of DNA damage sensor p-H2A.X, p53 and p21^waf^ were detected in tumor tissues. Compared to control treatment, SHK treatments dramatically increased the percentages of β-Gal-positive senescent cells in tumor tissues (**Figure [6D](#F6){ref-type="fig"}**). In addition, the expressions of p-H2A.X, p53 and p21^waf^ were also remarkably increased by SHK in a dose-dependent manner (**Figure [6E](#F6){ref-type="fig"}**).

Since p53-deleted H1299 cells is more sensitive than A549 cells to SHK (**Figure [1B](#F1){ref-type="fig"}**), we also evaluate the anti-tumor effects of SHK *in vivo* using H1299 xenograft model. Similar to the results in A549 xenograft model, SHK could effectively suppress tumor volume and tumor weight in H1299 xenograft mice model (**Figures [7A,B](#F7){ref-type="fig"}**). Compared to control treatment, 10 mg/kg of SHK remarkably inhibited tumor weights by 50.98%. Meanwhile, SHK treatment markedly increased the percentages of β-Gal-positive senescent cells in tumor tissues (**Figure [7C](#F7){ref-type="fig"}**). In addition, the expressions of p-H2A.X and p21^waf^ were also remarkably increased by SHK treatment (**Figure [7D](#F7){ref-type="fig"}**). No changes of the organ (heart, liver, spleen, lung, and kidney) indexes were found in all mice (Supplementary Figure [S2B](#SM1){ref-type="supplementary-material"}). H&E staining results also showed that no pathologic changes were observed in organs (heart, liver, and kidney) (Supplementary Figure [S2C](#SM1){ref-type="supplementary-material"}). These results suggested SHK could suppress lung tumorigenesis through stimulating cellular senescence.

![Anti-tumor effects of SHK in H1299 xenograft mice model. **(A)** Tumor volumes were analyzed. **(B)** Tumor weights were analyzed. **(C)** Images of senescence cells in tumor consecutive frozen sections using SA-β-Gal staining assay (scale bar: 50 μm). **(D)** Images of tumor p-H2A.X and p21^waf^ protein expressions were presented by immunohistochemistry (scale bar: 50 μm). ^∗^*P* \< 0.05 *vs*. Ctrl (control).](fphar-09-00519-g007){#F7}

Discussion
==========

In our study, the anti-tumor effect of SHK was determined and the senescence-involved mechanism was subsequently evaluated. We found that rather than inducing apoptosis, SHK predominantly stimulated cellular senescence via triggering DNA damage-p53/p21^waf^ axis. Moreover, SHK-induced senescence is closely dependent on intercellular ROS accumulation without activating oncogenes or suppressing TSG. Previous study demonstrated that cellular senescence activation could result in apparently opposite outcomes with either tumor suppressive or promoted effects in tumor initiation and progression ([@B35]). While the pro-senescence effect of SHK (10 mg/kg) led to strong tumor inhibition *in vivo* (55.84% in A549 xenograft mice, and 50.98% in H1299 xenograft mice, respectively), meanwhile, cell cycle, EdU, and apoptosis assays also revealed that SHK notably arrested cell proliferation and activated cellular apoptosis simultaneously. Wild-type p53 is a sequence-specific transcription factor that activates the transcription of downstream effector genes such as p21 et al., thereby preventing the transition from the G1 to the S phase of cell cycle ([@B38]). In our study, besides of stimulating the expression and phosphorylation of p53, SHK also notably increased the percentage of A549 and H1299 cells at G0/G1 phase.

Our study provides additional evidence to complement the correlation between ROS and senescence, and suggested the district mechanism underlying ROS-induced senescence and OIS. Previous study demonstrated that ROS-induced senescence is partially triggered by OIS, intercellular ROS accumulation is ascribe to activation of RAS-RAF-MEK-ERK pathway ([@B28]). On the contrary, we found that SHK significantly induced cellular senescence by accelerating ROS generation (**Figure [2C](#F2){ref-type="fig"}**) while inactivating oncogenes such as Ras and MEK-1 (**Figure [3A](#F3){ref-type="fig"}**), and meanwhile did not altering TSG such as RB (**Figure [3A](#F3){ref-type="fig"}**). This may suggest that ROS-induced senescence might be a combination progress of OIS and RS, and oncogene or TSG alterations are not essential driven factors. When ROS scavenger NAC is present, SHK-induced senescence were strongly diminished (**Figure [4C](#F4){ref-type="fig"}**), implied that SHK-induced senescence is closely dependent on ROS production than other molecular factors. Additionally, in a good agreement with another study, the negative correlation between ROS and oncogene expressions observed in our study suggested SHK may effectively reversed the over-activated oncogenes in tumors by physiologically enhanced ROS generation ([@B14]). Furthermore, ROS-induced senescence consequently induced DDR, p53, phosphorylated p53, and p21^waf^ (**Figures [3D,F](#F3){ref-type="fig"}**), and when ROS is depleted, DDR was subsequently suppressed (**Figure [4E](#F4){ref-type="fig"}**). Even in p53-depleted H1299 cells, senescence was also effectively stimulated by SHK through basal overexpressed p21^waf^ (**Figure [3E](#F3){ref-type="fig"}**). Moreover, knock-down of p21^waf^ significantly reversed SHK-induced senescence in both A549 and H1299 cells (**Figures [3F,G](#F3){ref-type="fig"}**), suggesting despite p53 phosphorylation ([@B29]), persistent p21^waf^ activation is the most predominant prerequisite for ROS-induced senescence. Taken previous reports and our findings together may inform the further study on ROS-induced senescence in following aspects: (i) ROS-dependent senescence, not relay on oncogenes activation, is partially district from OIS, some alternative mechanism may underlying and need extensively investigation; (ii) p53 activation and phosphorylation could promote ROS-induced senescence, while p21^waf^ overexpression is the predominant driver.

Our findings uncovered the proportion and predominant role of senescence and apoptosis involved in anti-tumor effects of SHK. Although the concept of "senescence" is firstly found in 1965 by Leonard Hayflick, the usage of it as a cancer therapy strategy is underestimated and little excited pro-senescence agents were discovered ([@B31]). This may partially due to the concerns of whether the senescent cells will relay on anti-apoptosis pathway to persist in tissues? And how the senescent cells will be cleaned up? We found that SHK significantly induced senescence and apoptosis at the same time (**Figures [2](#F2){ref-type="fig"}**, **[5](#F5){ref-type="fig"}**). While compared to the abundantly stimulated senescence in A549 cell (range 38.70%--70.69%, **Figure [2C](#F2){ref-type="fig"}**), the percentage of total apoptosis is extremely low (range 3.13%--7.65%, **Figure [5A](#F5){ref-type="fig"}**), which implied that rather than apoptosis, the predominant mechanism responsible for the anti-tumor effect of SHK was ascribed to senescence stimulation. Meanwhile, SHK markedly decreased anti-apoptosis protein Bcl-2 while increased pro-apoptotic Bax (**Figure [5B](#F5){ref-type="fig"}**), suggested that SHK-induced senescent cells could be further and gradually cleaned up by SHK-induced apoptosis. Other studies also revealed that senescence stimulate immunosurveillance to eliminate tumor cells ([@B11]; [@B34]), therefore, the effects of SHK on immune cells such as natural killer cells, T, B, and macrophages need to be further determined. Furthermore, compared to cytotoxic chemotherapeutic agents such as doxorubicin, vincristine, and cyclophosphamide, the pro-senescence agents could provide an alternative opportunity to avoid systemic toxicities by stimulating intrinsic anti-tumor response ([@B40]). In xenograft model, we also observed that SHK-induced senescence remarkably suppressed tumor growth without altering body weight during 4 weeks of treatment (**Figures [6A](#F6){ref-type="fig"}**). Moreover, No changes of the organ (heart, liver, spleen, lung, and kidney) indexes were found in all mice, and no pathologic changes were observed in organs (heart, liver, and kidney) (Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}), suggesting no observed systemic toxicities were induced by SHK.

Taken together, by determining the pro-senescence mechanism of SHK in lung cancer cells, our present study advances our understanding of ROS-induced senescence and the anti-tumor effect of SHK in following aspects: (i) ROS-dependent senescence, not relay on oncogenes activation, is partially district from OIS, which implied that some alternative mechanisms may underlying and need extensively investigation; (ii) p53 activation and phosphorylation could promote ROS-induced senescence, while p21^waf^ overexpression might be the predominant driver; (iii) SHK may predominantly stimulate ROS-dependent senescence, while simultaneously accelerate cellular apoptosis program to eliminate the senescent tumor cells. The subsequently triggered pro-apoptosis pathway laid foundation to the further regard SHK as promising anti-tumor agents. However, considering the low proportion of apoptosis induced by SHK, other cleaned up mechanisms such as immunosurveillance, autophagy, and necrosis need to be further determined on SHK-induced senescence.

Conclusion
==========

SHK could induce cellular senescence through stimulating ROS generation and subsequently triggering DNA damage-p53/p21^waf^ axis. SHK, a ROS-dependent senescence inducer, could serve as a promising agent for further lung cancer treatment.
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DDR

:   DNA damage response

EdU

:   5-ethynyl-2′-deoxyuridine

LAC

:   Lung adenocarcinoma

MTT

:   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NAC

:   *N*-Acetyl-[L]{.smallcaps}-Cysteine

OIS

:   oncogene-induced senescence

PI

:   propidium iodide

PICS

:   PTEN loss-induced cellular senescence

PMSF

:   phenylmethanesulfonyl fluoride

ROS

:   reactive oxygen species

RS

:   replicative senescence

SA-β-Gal

:   senescence-associated β-galactosidase

SAHF

:   senescence-associated heterochromatin foci

SHK

:   shikonin

TSG

:   tumor suppressor genes
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